Emerging technologies for quality control of cell-based, advanced therapy medicinal products

J Pharm Biomed Anal. 2024 Aug 15:246:116182. doi: 10.1016/j.jpba.2024.116182. Epub 2024 Apr 29.

Abstract

Advanced therapy medicinal products (ATMP) are complex medicines based on gene therapy, somatic cell therapy, and tissue engineering. These products are rapidly arising as novel and promising therapies for a wide range of different clinical applications. The process for the development of well-established ATMPs is challenging. Many issues must be considered from raw material, manufacturing, safety, and pricing to assure the quality of ATMPs and their implementation as innovative therapeutic tools. Among ATMPs, cell-based ATMPs are drugs altogether. As for standard drugs, technologies for quality control, and non-invasive isolation and production of cell-based ATMPs are then needed to ensure their rapidly expanding applications and ameliorate safety and standardization of cell production. In this review, emerging approaches and technologies for quality control of innovative cell-based ATMPs are described. Among new techniques, microfluid-based systems show advantages related to their miniaturization, easy implementation in analytical process and automation which allow for the standardization of the final product.

Keywords: Advanced therapy medicinal products (ATMPs); Machine learning and AI; Microfluidic tools for QC of ATMPs; Quality control (QC) of ATMPs; Quality-by-design (QBD).

Publication types

  • Review

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy* / methods
  • Cell- and Tissue-Based Therapy* / standards
  • Genetic Therapy* / methods
  • Genetic Therapy* / standards
  • Humans
  • Quality Control
  • Tissue Engineering* / methods
  • Tissue Engineering* / standards